Thrombin inhibitors identified by computer-assisted multiparameter design

被引:29
作者
Riester, D
Wirsching, F
Salinas, G
Keller, M
Gebinoga, M
Kamphausen, S
Merkwirth, C
Goetz, R
Wiesenfeldt, M
Stürzebecher, J
Bode, W
Friedrich, R
Thürk, M
Schwienhorst, A
机构
[1] Matrix Adv Solut Ltd, London W1J 8DY, England
[2] Inst Mikrobiol & Genet, Abt Mol Genet & Praparat Molekularbiol, D-37077 Gottingen, Germany
[3] Novel Sci Int GmbH, D-30159 Hannover, Germany
[4] Univ Jena, Zentrum Vaskulare Biol & Med, D-99089 Erfurt, Germany
[5] Max Planck Inst Biochem, Abt Strukturforsch, D-82152 Martinsried, Germany
关键词
crystallographic structure; drug design; early adsorption; toxicity; genetic algorithm;
D O I
10.1073/pnas.0501983102
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 [理学]; 0710 [生物学]; 09 [农学];
摘要
Here, we present a series of thrombin inhibitors that were generated by using powerful computer-assisted multiparameter optimization process. The process was organized in design cycles, starting with a set of randomly chosen molecules. Each cycle combined combinatorial synthesis, multiparameter characterization of compounds in a variety of bioassays, and algorithmic processing of the data to devise a set of compounds to be synthesized in the next cycle. The identified lead compounds exhibited thrombin inhibitory constants in the lower nanomolar range. They are by far the most selective synthetic thrombin inhibitors, with selectivities of > 100,000-fold toward other proteases such as Factor Xa, Factor XIIa, urokinase, plasmin, and Plasma kallikrein. Furthermore, these compounds exhibit a favorable profile, comprising nontoxicity, high metabolic stability, low serum protein binding, good solubility, high anticoagulant activity, and a slow and exclusively renal elimination from the circulation in a rat model. Finally, x-ray crystallographic analysis of a thrombin-inhibitor complex revealed a binding mode with a neutral moiety in the S1 pocket of thrombin.
引用
收藏
页码:8597 / 8602
页数:6
相关论文
共 19 条
[1]
Factorising ligand affinity:: A combined thermodynamic and crystallographic study of trypsin and thrombin inhibition [J].
Dullweber, F ;
Stubbs, MT ;
Musil, D ;
Stürzebecher, J ;
Klebe, G .
JOURNAL OF MOLECULAR BIOLOGY, 2001, 313 (03) :593-614
[2]
Gustafsson D, 1998, THROMB HAEMOSTASIS, V79, P110
[3]
The direct thrombin inhibitor melagatran and its oral prodrug H 376/95:: Intestinal absorption properties, biochemical and pharmacodynamic effects [J].
Gustafsson, D ;
Nyström, JE ;
Carlsson, S ;
Bredberg, U ;
Eriksson, U ;
Gyzander, E ;
Elg, M ;
Antonsson, T ;
Hoffmann, KJ ;
Ungell, AL ;
Sörensen, H ;
Någård, S ;
Abrahamsson, A ;
Bylund, R .
THROMBOSIS RESEARCH, 2001, 101 (03) :171-181
[4]
Synthetic inhibitors of thrombin and factor Xa:: From bench to bedside [J].
Hauptmann, J ;
Stürzebecher, J .
THROMBOSIS RESEARCH, 1999, 93 (05) :203-241
[5]
Influence of structural variations in peptidomimetic 4-amidinophenylalanine-derived thrombin inhibitors on plasma clearance and biliary excretion in rats [J].
Hauptmann, J ;
Steinmetzer, T ;
Vieweg, H ;
Wikström, P ;
Stürzebecher, J .
PHARMACEUTICAL RESEARCH, 2002, 19 (07) :1027-1033
[6]
Genetic algorithm for the design of molecules with desired properties [J].
Kamphausen, S ;
Höltge, N ;
Wirsching, F ;
Morys-Wortmann, C ;
Riester, D ;
Goetz, R ;
Thürk, M ;
Schwienhorst, A .
JOURNAL OF COMPUTER-AIDED MOLECULAR DESIGN, 2002, 16 (8-9) :551-567
[7]
Lyle EM, 1998, THROMB HAEMOSTASIS, V79, P656
[9]
Okada Y, 1999, BIOPOLYMERS, V51, P41, DOI 10.1002/(SICI)1097-0282(1999)51:1<41::AID-BIP5>3.0.CO
[10]
2-Y